Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8049 USD | +1.89% | +1.89% | -15.04% |
Sales 2024 * | 2.33M 195M | Sales 2025 * | 3.33M 278M | Capitalization | 58.6M 4.89B |
---|---|---|---|---|---|
Net income 2024 * | -102M -8.5B | Net income 2025 * | -111M -9.25B | EV / Sales 2024 * | 25.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 17.6 x |
P/E ratio 2024 * |
-0.6
x | P/E ratio 2025 * |
-0.64
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.19% |
Latest transcript on Kezar Life Sciences, Inc.
1 day | +1.89% | ||
1 week | +1.89% | ||
Current month | -10.73% | ||
1 month | -9.96% | ||
3 months | -2.97% | ||
6 months | +0.98% | ||
Current year | -15.04% |
Managers | Title | Age | Since |
---|---|---|---|
Christopher Kirk
FOU | Founder | 52 | 19/15/19 |
John Fowler
FOU | Founder | 52 | 19/15/19 |
Marc Belsky
DFI | Director of Finance/CFO | 68 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 01/16/01 |
Graham Cooper
CHM | Chairman | 54 | 01/17/01 |
Michael Kauffman
BRD | Director/Board Member | 60 | 01/16/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.8049 | +1.89% | 496,295 |
25/24/25 | 0.79 | -1.42% | 577,569 |
24/24/24 | 0.8014 | -2.98% | 445,607 |
23/24/23 | 0.826 | +0.49% | 518,861 |
22/24/22 | 0.822 | +4.05% | 709,557 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.04% | 58.6M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- KZR Stock